Adventrx Pharma Acquiring SynthRx
Adventrx Pharmaceuticals, a specialty pharmaceutical company engaged in acquiring, developing and commercializing proprietary product candidates, has taken over SynthRx, under a definitive merger agreement signed between the companies in February 2011.
Following the acquisition, SynthRx's lead product candidate, poloxamer 188, a novel, proprietary, rheologic and antithrombotic compound, will be developed by Adventrx as ANX-188.
Adventrx CEO Brian Culley said their plan to meet with FDA this year to reach agreement on a protocol for a pivotal phase 3 study for treatment of sickle cell crisis in a pediatric population, an orphan indication.
April 15, 2011